Latest Genentech Stories
TARRYTOWN, N.Y., Oct. 17, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
-- Fourth indication for injection treatment that can stabilize and improve vision(1) -- mCNV a leading cause of visual impairment among those 20-50 years of age(9) Since
In the news release, The Gastric Cancer Market is Expected to More Than Triple Over the Next Ten Years, Capturing Nearly $3.8 million by 2023, issued 18-Sep-2014 by Decision
BASEL, Switzerland, Sept. 29, 2014 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) and InterMune, Inc.
Fovista and Abicipar Pegol Will Need to be Priced Competitively to Current Agents to Garner Favorable Tier Placement, According to Findings from Decision Resources Group BURLINGTON, Mass.,
Several Emerging Therapies Will Expand Treatment Armamentarium for Unresectable Locally Advanced or Metastatic Gastric Cancer, According to Findings from Decision Resources Group BURLINGTON,
DUBLIN and MELBOURNE, Australia, Sept. 18, 2014 /PRNewswire/ -- Veterinary biologic therapy developer Nexvet Biopharma today announced the appointments of Dr.
- Calico to create a leading R&D facility in the San Francisco Bay Area focused on aging and age-related diseases, including neurodegeneration and cancer NORTH CHICAGO, Ill.
-- Roche to acquire InterMune for $74.00 per share -- BASEL, Switzerland, Aug. 24, 2014 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) and InterMune, Inc.
- A poem in which the author retracts something said in an earlier poem.